International
The Morning Science

What science found today

‹
 

Research

Two new 16-week tuberculosis regimens advance in clinical trial

Medical Xpress ·

Two new 16-week tuberculosis regimens advance in clinical trial

The Brief

  • Two new 16-week tuberculosis treatment regimens have advanced in a clinical trial.
  • Tuberculosis causes more than 1 million deaths each year, according to the source.
  • Current TB treatment is described as lengthy and burdened by side effects.

Why it matters

Shorter TB regimens could reduce treatment duration and side-effect burden for patients, which matters for global infectious disease control.

Who’s affected

  • clinicians and public health officials working on tuberculosis
  • researchers in infectious disease and drug development

Tuberculosis remains one of the world's deadliest infectious diseases, causing more than 1 million deaths each year. The development of new therapeutic regimens remains slow, costly and complex, while treatment remains lengthy and patients face the burden of side effects…

Timeline

  1. Medical Xpress reports that two new 16-week tuberculosis regimens advance in clinical trial

  2. Medical Xpress - latest medical and health news stories

    Two new 16-week tuberculosis regimens advance in clinical trial

How do you feel about this?

0 Comments